Shots:
- The EC has approved MB02 biosimilar to Avastin (Bevacizumab) in the EU for the treatment of carcinoma of the colon or rectum, BC, NSCLC, RCC, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix
- Mabxience’s MB02 to be marketed as Alymsys and Oyavas both show comparable quality, safety & efficacy to Avastin (bevacizumab)
- The launch of Bevacizumab has provided high quality, affordable medicine and opportunity to the healthcare system and improve patient access to biological treatments throughout the EU
Click here to read full press release/ article | Ref: PRNewswire | Image: Adobe Stock
The post mAbxience’s MB02 (biosimilar, bevacizumab) Receives EC’s Approval for the Treatment of Cancer first appeared on PharmaShots.